| NCT04031742 |
A Study to Evaluate Safety and Efficacy of IBI306, a PCSK9 Monoclonal Antibody in Chinese Subjects With Homozygous Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT04031742 |
Recruiting |
Innovent Biologics (Suzhou) Co. Ltd. |
2021-01-13 |
| NCT03409744 |
Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT03409744 |
Enrolling by invitation |
Regeneron Pharmaceuticals |
2022-04-18 |
| NCT03397121 |
Trial to Evaluate the Effect of Inclisiran Treatment on Low Density Lipoprotein Cholesterol (LDL-C) in Subjects With Heterozygous Familial Hypercholesterolemia (HeFH) |
https://ClinicalTrials.gov/show/NCT03397121 |
Active, not recruiting |
The Medicines Company |
2019-09-27 |
| NCT03331666 |
Impact of LDL-cholesterol Lowering on Platelet Activation |
https://ClinicalTrials.gov/show/NCT03331666 |
Recruiting |
Columbia University |
2021-07-01 |
| NCT03234127 |
Study of cardiovAscular Contrasted Phenotypes in Patients With FamIliaI hypercholesteRolemia |
https://ClinicalTrials.gov/show/NCT03234127 |
Recruiting |
Nantes University Hospital |
2020-11-30 |
| NCT03156621 |
Study in Participants With Homozygous Familial Hypercholesterolemia (HoFH) |
https://ClinicalTrials.gov/show/NCT03156621 |
Completed |
Regeneron Pharmaceuticals |
2019-09-27 |
| NCT03135184 |
HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT03135184 |
Active, not recruiting |
HDL Therapeutics |
2019-01-07 |
| NCT03060577 |
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol |
https://ClinicalTrials.gov/show/NCT03060577 |
Active, not recruiting |
The Medicines Company |
2018-08-29 |
| NCT03038022 |
Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) |
https://ClinicalTrials.gov/show/NCT03038022 |
Completed |
Madrigal Pharmaceuticals, Inc. |
2017-12-18 |
| NCT02963311 |
A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH) |
https://ClinicalTrials.gov/show/NCT02963311 |
Completed |
The Medicines Company |
2018-10-08 |
| NCT02890992 |
An 8-Week Dose-Finding Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT02890992 |
Completed |
Sanofi |
2018-09-13 |
| NCT02748057 |
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Participants With Hypercholesterolemia (MK-0653H-833) |
https://ClinicalTrials.gov/show/NCT02748057 |
Completed |
Merck Sharp & Dohme Corp. |
2017-12-11 |
| NCT02729857 |
Postprandial Response After Intake of Meals With Different Fatty Acid Composition |
https://ClinicalTrials.gov/show/NCT02729857 |
Completed |
University of Oslo |
2016-06-30 |
| NCT02722408 |
Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1) |
https://ClinicalTrials.gov/show/NCT02722408 |
Completed |
NeuroBo Pharmaceuticals Inc. |
2017-04-30 |
| NCT02709850 |
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Participants With Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT02709850 |
Completed |
Ionis Pharmaceuticals, Inc. |
2017-04-12 |
| NCT02651675 |
A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH) |
https://ClinicalTrials.gov/show/NCT02651675 |
Active, not recruiting |
Regenxbio Inc. |
2022-07-31 |
| NCT02624869 |
Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia (HeFH) or Homozygous Familial Hypercholesterolemia (HoFH). |
https://ClinicalTrials.gov/show/NCT02624869 |
Active, not recruiting |
Amgen |
2021-06-07 |
| NCT02597127 |
Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C) |
https://ClinicalTrials.gov/show/NCT02597127 |
Completed |
The Medicines Company |
2017-06-07 |
| NCT03403374 |
Safety and Tolerability of Repatha in Indian Subjects With Homozygous Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT03403374 |
Completed |
Amgen |
2019-11-27 |
| NCT03399786 |
Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT03399786 |
Completed |
Regeneron Pharmaceuticals |
2019-06-10 |
| NCT02472535 |
Study to Evaluate the Effects of MBX-8025 in Patients With HoFH |
https://ClinicalTrials.gov/show/NCT02472535 |
Completed |
CymaBay Therapeutics, Inc. |
2016-02-29 |
| NCT02462655 |
Effects of LDL Apheresis System on the Expression of Genes Involved in Lipoprotein Metabolism and Inflammation in Homozygotes for Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT02462655 |
Completed |
Laval University |
2015-12-31 |
| NCT02460159 |
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384) |
https://ClinicalTrials.gov/show/NCT02460159 |
Completed |
Merck Sharp & Dohme Corp. |
2016-12-22 |
| NCT02434497 |
A Study to Evaluate the Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT02434497 |
Completed |
AstraZeneca |
2016-11-17 |
| NCT02392559 |
Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders |
https://ClinicalTrials.gov/show/NCT02392559 |
Completed |
Amgen |
2019-11-25 |
| NCT02326220 |
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy |
https://ClinicalTrials.gov/show/NCT02326220 |
Completed |
Regeneron Pharmaceuticals |
2016-01-31 |
| NCT02265952 |
Study of REGN1500 in Participants With Homozygous Familial Hypercholesterolemia (HoFH) |
https://ClinicalTrials.gov/show/NCT02265952 |
Completed |
Regeneron Pharmaceuticals |
2016-11-21 |
| NCT02226198 |
A Study to Evaluate the Efficacy and Safety of Rosuvastatin in Children and Adolescents With Homozygous Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT02226198 |
Completed |
AstraZeneca |
2015-07-31 |
| NCT02173158 |
Efficacy and Safety of Lomitapide in Japanese Patients With HoFH on Concurrent Lipid-Lowering Therapy |
https://ClinicalTrials.gov/show/NCT02173158 |
Completed |
Aegerion Pharmaceuticals, Inc. |
2015-04-03 |
| NCT02107898 |
Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYSSEY JAPAN) |
https://ClinicalTrials.gov/show/NCT02107898 |
Completed |
Sanofi |
2015-01-31 |
| NCT02048410 |
Efficacy of a New Symbiotic Formulation in Children With Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT02048410 |
Completed |
Federico II University |
2012-09-30 |
| NCT01995149 |
Effect of Weight Loss on Cholesterol Metabolism in Hereditary Hypercholesterolemias and Overweight or Obesity. |
https://ClinicalTrials.gov/show/NCT01995149 |
Completed |
Instituto Aragones de Ciencias de la Salud |
2012-09-30 |
| NCT01824238 |
A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy in Japanese Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-050) |
https://ClinicalTrials.gov/show/NCT01824238 |
Completed |
Merck Sharp & Dohme Corp. |
2014-05-31 |
| NCT01813006 |
Effect of Omega-3 Fatty Acid on Endothelial Function |
https://ClinicalTrials.gov/show/NCT01813006 |
Completed |
Nordlandssykehuset HF |
2016-12-31 |
| NCT01763918 |
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2 |
https://ClinicalTrials.gov/show/NCT01763918 |
Completed |
Amgen |
2013-11-27 |
| NCT01709500 |
Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy) |
https://ClinicalTrials.gov/show/NCT01709500 |
Completed |
Regeneron Pharmaceuticals |
2014-05-31 |
| NCT01624142 |
Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders |
https://ClinicalTrials.gov/show/NCT01624142 |
Completed |
Amgen |
2018-05-11 |
| NCT01623115 |
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy |
https://ClinicalTrials.gov/show/NCT01623115 |
Completed |
Sanofi |
2014-04-30 |
| NCT01617655 |
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH) |
https://ClinicalTrials.gov/show/NCT01617655 |
Completed |
Sanofi |
2014-05-31 |
| NCT01604824 |
A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene |
https://ClinicalTrials.gov/show/NCT01604824 |
Completed |
Regeneron Pharmaceuticals |
2014-06-02 |
| NCT01588496 |
Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities |
https://ClinicalTrials.gov/show/NCT01588496 |
Completed |
Amgen |
2014-01-31 |
| NCT01556906 |
Safety, Tolerability and Efficacy of Microsomal Triglyceride Protein (MTP) Inhibitor |
https://ClinicalTrials.gov/show/NCT01556906 |
Completed |
Aegerion Pharmaceuticals, Inc. |
2004-02-29 |
| NCT01524289 |
Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020) |
https://ClinicalTrials.gov/show/NCT01524289 |
Completed |
Merck Sharp & Dohme Corp. |
2014-02-12 |
| NCT01515241 |
Exploratory Study of Plaque Regression |
https://ClinicalTrials.gov/show/NCT01515241 |
Completed |
Cerenis Therapeutics, SA |
2012-04-30 |
| NCT01475825 |
A Study of the Safety and Efficacy of Two Different Regimens of Mipomersen in Patients With Familial Hypercholesterolemia and Inadequately Controlled Low-Density Lipoprotein Cholesterol |
https://ClinicalTrials.gov/show/NCT01475825 |
Completed |
Kastle Therapeutics, LLC |
2015-12-29 |
| NCT01412034 |
Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects |
https://ClinicalTrials.gov/show/NCT01412034 |
Completed |
Cerenis Therapeutics, SA |
2013-10-31 |
| NCT01388816 |
A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol Levels |
https://ClinicalTrials.gov/show/NCT01388816 |
Completed |
Dr. Reddy’s Laboratories Limited |
2012-05-31 |
| NCT01375751 |
Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study |
https://ClinicalTrials.gov/show/NCT01375751 |
Completed |
Amgen |
2012-05-16 |
| NCT04179669 |
Safety and Efficacy of IBI306 in HeFH Patients |
https://ClinicalTrials.gov/show/NCT04179669 |
Recruiting |
Innovent Biologics (Suzhou) Co. Ltd. |
2022-12-31 |
| NCT04118348 |
Evaluating the Efficacy of Pediatric Lipid Screening Alerts |
https://ClinicalTrials.gov/show/NCT04118348 |
Enrolling by invitation |
Geisinger Clinic |
2020-10-31 |
| NCT03934320 |
Improving Identification of Familial Hypercholesterolaemia in Primary Care (FAMCAT) |
https://ClinicalTrials.gov/show/NCT03934320 |
Enrolling by invitation |
University of Nottingham |
2020-07-31 |
| NCT03933293 |
A Study to Evaluate the Safety and Efficacy of the PCSK9 Inhibitor AK102 in Patients With HoFH |
https://ClinicalTrials.gov/show/NCT03933293 |
Recruiting |
Akeso |
2021-02-28 |
| NCT03885921 |
Safety and Tolerability Study of Ezetimibe (SCH 058235/MK-0653) Plus Atorvastatin or Simvastatin in Homozygous Familial Hypercholesterolemia (P01417/MK-0653-019) |
https://ClinicalTrials.gov/show/NCT03885921 |
Completed |
Merck Sharp & Dohme Corp. |
2003-07-08 |
| NCT03884452 |
Ezetimibe (SCH 58235) Taken With Either Atorvastatin or Simvastatin in Participants With Familial Hypercholesterolemia (MK-0653-018) |
https://ClinicalTrials.gov/show/NCT03884452 |
Completed |
Merck Sharp & Dohme Corp. |
2001-05-24 |
| NCT03851705 |
A Study of Inclisiran in Participants With Homozygous Familial Hypercholesterolemia (HoFH) |
https://ClinicalTrials.gov/show/NCT03851705 |
Active, not recruiting |
The Medicines Company |
2020-03-02 |
| NCT03832985 |
Pediatric Reporting of Adult-Onset Genomic Results |
https://ClinicalTrials.gov/show/NCT03832985 |
Recruiting |
Geisinger Clinic |
2023-06-30 |
| NCT03814187 |
Trial to Assess the Effect of Long Term Dosing of Inclisiran in Subjects With High CV Risk and Elevated LDL-C |
https://ClinicalTrials.gov/show/NCT03814187 |
Active, not recruiting |
The Medicines Company |
2023-08-31 |
| NCT03795038 |
Comparison of the Plasma Lipoprotein Apheresis Systems DIAMED and MONET vs. the Whole Blood Apheresis System DALI |
https://ClinicalTrials.gov/show/NCT03795038 |
Recruiting |
Fresenius Medical Care Deutschland GmbH |
2019-12-31 |
| NCT03747224 |
Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients |
https://ClinicalTrials.gov/show/NCT03747224 |
Recruiting |
Arrowhead Pharmaceuticals |
2020-05-30 |
| NCT03563547 |
Effects of Soy Protein on Cholesterol Levels in Children Affected With Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT03563547 |
Completed |
Austrian Academic Institute for Clinical Nutrition |
2014-10-09 |
| NCT03510884 |
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT03510884 |
Recruiting |
Sanofi |
2020-08-18 |
| NCT03510715 |
An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT03510715 |
Completed |
Sanofi |
2020-02-17 |
| NCT03501875 |
Study of Coronary Calcification in Subjects With Autosomal Dominant Familial Hypercholesterolemia Heterozygous |
https://ClinicalTrials.gov/show/NCT03501875 |
Active, not recruiting |
Assistance Publique - Hôpitaux de Paris |
2021-02-01 |
| NCT01078675 |
An Study to Evaluate Rosuvastatin in Children and Adolescents With Familial Hypercholesterolaemia |
https://ClinicalTrials.gov/show/NCT01078675 |
Completed |
AstraZeneca |
2013-02-28 |
| NCT00943306 |
Long Term, Follow-on Study of Lomitapide in Patients With Homozygous Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT00943306 |
Completed |
Aegerion Pharmaceuticals, Inc. |
2012-09-17 |
| NCT00916643 |
Low-Density Lipoprotein (LDL) Apheresis Using H.E.L.P. Therapy |
https://ClinicalTrials.gov/show/NCT00916643 |
Completed |
B. Braun Medical Inc. |
2009-09-30 |
| NCT04034485 |
Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH |
https://ClinicalTrials.gov/show/NCT04034485 |
Enrolling by invitation |
LIB Therapeutics LLC |
2021-03-31 |
| NCT00827606 |
Atorvastatin Three Year Pediatric Study |
https://ClinicalTrials.gov/show/NCT00827606 |
Completed |
Pfizer |
2013-10-31 |
| NCT01968980 |
A 52 Week Study To Assess The Use Of Bococizumab (PF-04950615; RN316) In Subjects With Heterozygous Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT01968980 |
Completed |
Pfizer |
2016-04-15 |
| NCT00739999 |
8-Week PK/PD Atorvastatin Study In Children And Adolescents With Heterozygous Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT00739999 |
Completed |
Pfizer |
2009-05-31 |
| NCT00730236 |
A Safety and Efficacy Study of AEGR-733 to Treat Homozygous Familial Hypercholesterolemia (FH) |
https://ClinicalTrials.gov/show/NCT00730236 |
Completed |
Aegerion Pharmaceuticals, Inc. |
2010-09-30 |
| NCT00706849 |
Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease |
https://ClinicalTrials.gov/show/NCT00706849 |
Completed |
Kastle Therapeutics, LLC |
2009-12-31 |
| NCT00694109 |
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of ISIS 301012 (Mipomersen) in Patients With Familial Hypercholesterolemia or Severe-Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT00694109 |
Completed |
Kastle Therapeutics, LLC |
2014-09-30 |
| NCT00688896 |
Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia |
https://ClinicalTrials.gov/show/NCT00688896 |
Completed |
Akros Pharma Inc. |
2003-04-30 |
| NCT00686010 |
Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia |
https://ClinicalTrials.gov/show/NCT00686010 |
Completed |
Japan Tobacco Inc. |
2001-01-31 |
| NCT00655265 |
A Study of the Safety and Efficacy of Patients With Familial Hypercholesterolaemia Taking Colesevelam as add-on Therapy to Their Existing Medication |
https://ClinicalTrials.gov/show/NCT00655265 |
Completed |
Sanofi |
2008-12-31 |
| NCT00607373 |
Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT00607373 |
Completed |
Kastle Therapeutics, LLC |
2009-03-31 |
| NCT00515307 |
Bone Marrow Stem Cells as a Source of Allogenic Hepatocyte Transplantation in Homozygous Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT00515307 |
Completed |
University of Tehran |
2008-05-31 |
| NCT00477594 |
Open Label Extension of ISIS 301012 (Mipomersen) to Treat Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT00477594 |
Completed |
Kastle Therapeutics, LLC |
2011-03-31 |
| NCT00473655 |
Effect of Rosuvastatin on Triglyceride Levels in Mexican Hypertriglyceridemic Patients |
https://ClinicalTrials.gov/show/NCT00473655 |
Completed |
AstraZeneca |
2009-02-28 |
| NCT00355615 |
PLUTO: Pediatric Lipid-redUction Trial of rOsuvastatin |
https://ClinicalTrials.gov/show/NCT00355615 |
Completed |
AstraZeneca |
2008-07-31 |
| NCT00281008 |
Study of ISIS 301012 (Mipomersen) in Heterozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy |
https://ClinicalTrials.gov/show/NCT00281008 |
Completed |
Kastle Therapeutics, LLC |
2007-07-31 |
| NCT00280995 |
Dose-escalating Safety Study of ISIS 301012 in Homozygous Familial Hypercholesterolemia Subjects on Lipid Lowering Therapy |
https://ClinicalTrials.gov/show/NCT00280995 |
Completed |
Kastle Therapeutics, LLC |
2007-04-30 |
| NCT00171236 |
Efficacy and Safety of Fluvastatin in Children With Heterozygous Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT00171236 |
Completed |
Novartis |
2005-03-31 |
| NCT00136981 |
Carotid B-Mode Ultrasound Study to Compare Anti-Atherosclerotic Effect of Torcetrpib/Atorvastatin to Atorvastatin Alone. |
https://ClinicalTrials.gov/show/NCT00136981 |
Completed |
Pfizer |
NA |
| NCT00134511 |
Study To Evaluate The Effect Of Torcetrapib/Atorvastatin In Patients With Genetic High Cholesterol Disorder |
https://ClinicalTrials.gov/show/NCT00134511 |
Completed |
Pfizer |
NA |
| NCT00134485 |
Study To Evaluate The Safety And Efficacy Of Torcetrapib/Atorvastatin In Subjects With Familial Hypercholerolemia |
https://ClinicalTrials.gov/show/NCT00134485 |
Completed |
Pfizer |
NA |
| NCT00004809 |
Phase I Study of Ex Vivo Liver-Directed Gene Therapy for Familial Hypercholesterolemia |
https://ClinicalTrials.gov/show/NCT00004809 |
Completed |
Office of Rare Diseases (ORD) |
NA |
| NCT00000594 |
NHLBI Type II Coronary Intervention Study |
https://ClinicalTrials.gov/show/NCT00000594 |
Completed |
National Heart, Lung, and Blood Institute (NHLBI) |
NA |